Market capitalization | $42.06m |
Enterprise Value | $-104.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.32 |
EV/Sales (TTM) EV/Sales | -14.93 |
P/S ratio (TTM) P/S ratio | 6.01 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue (TTM) Revenue | $7.00m |
EBIT (operating result TTM) EBIT | $-99.54m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Kezar Life Sciences Inc forecast:
6 Analysts have issued a Kezar Life Sciences Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -102 -102 |
49%
49%
|
|
Depreciation and Amortization | 1.07 1.07 |
5%
5%
|
|
Stock Compensation | 18 18 |
29%
29%
|
|
Operating Cash Flow | -82 -82 |
39%
39%
|
|
Investments | 1.81 1.81 |
15%
15%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -83 -83 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Christopher Kirk |
Employees | 58 |
Founded | 2015 |
Website | www.kezarlifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.